Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. et al, No. 2:15-cv-01455 (E.D. Tex. Aug. 25, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Before the Court are the parties’ submissions regarding the declaratory judgment claims under 35 U.S.C. § 271(a), (b), and (c), Dkt. Nos. 405 and 406, and regarding the request of plaintiff Allergan, Inc., for notice before any at -risk launch by any defendant, Dkt. Nos. 407 and 408. After consideration of the briefs filed by the parties, the Court will not at this time order the defendants to give Allergan seven days’ advance notice of any at -risk launch.